Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims

Current Medical Research and Opinion

Volumn 26, Issue 4, 2010, Pages 777-785

  Copher, R ^a   Buzinec, P ^a   Zarotsky, V ^b   Kazis, L ^c   Iqbal, S U ^d   MacArios, D ^d  

^a i3 Innovus   (United States)

^b School of Public Health ^*  (United States)

^c BOSTON UNIVERSITY   (United States)

^d AMGEN INC   (United States)

Author keywords

Data collection; Medication adherence; Osteoporosis; Physicians; Postmenopausal; Survey

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ARTICLE; BILLING AND CLAIMS; CONTROLLED STUDY; HUMAN; OSTEOPOROSIS; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; QUESTIONNAIRE; TREATMENT REFUSAL; UNITED STATES;

AGED; BONE DENSITY CONSERVATION AGENTS; CROSS-SECTIONAL STUDIES; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; PHYSICIAN-PATIENT RELATIONS; PRIMARY HEALTH CARE; REGRESSION ANALYSIS; UNITED STATES;

EID: 77949528464     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903579171     Document Type: Article

References (25)

1. National Osteoporosis Foundation.Fast Facts 2006. Washington, DC: National Osteoporosis Foundation. Available at: www.nof.org/osteoporosis/ disease-facts.htm [Last accessed 11 May 2009]
2. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-475
3. Gupta G, Aronow WS. Treatment of postmenopausal osteoporosis [review]. Compr Ther 2007;33:114-119
4. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-1008
5. Siris E, Rosen CJ, Harris ST, et al. Adherence to bisphosphonate therapy: relationship to bone fractures at 24 months in women with postmenopausal osteoporosis. Abstract 397. Presented at the Sixth International Symposium on Osteoporosis, National Osteoporosis Foundation, Washington, DC, April 7, 2005
6. Sebaldt RJ, Shane LG, Pham BZ, et al. Impact of non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis. Poster M423. Presented at the 26th Annual Meeting of the American Society for Bone and Mineral Research, Seattle, Washington, October 1-5, 2004
7. Thier SL, Yu-Isenberg KS, Leas BF, et al. In chronic disease, nationwide data show poor adherence by patients to medication and by physicians to guidelines. Manag Care 2008;17:48-52,55-57
8. Warriner AH, Curtis JR. Adherence to osteoporosis treatments: room for improvement. Curr Opin Rheumatol 2009;21:356-362
9. Gleeson T, Iversen MD, Avorn J, et al. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 2009; Jun 5 [Epub ahead of print]
10. Kothawala P, Badamgarav E, Ryu S, et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007;82:1493-1501
11. McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-287
12. Lekkerkerker F, Kanis JA, Alsayed N, et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 2007;18:1311-1317
13. Rabenda V, Hilligsmann M, Reginster JY. Poor adherence to oral bispho-sphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 2009;10:2203-2215
14. Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009;122 (2 Suppl.):S3-13
15. Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14:965-968
16. Delmas PD, Vrijens B, Eastell R, et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2007;92:1296-1304
17. Eastell R, Garnero P, Vrijens B, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 2003;72:408. Abstract P-297
18. Gold DT, Alexander IM, Ettinger MP. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. Ann Pharmacother 2006;40:1143-1150
19. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
20. Sikka, R, Xia F, Aubert RE. Estimating medication persistency using administration claims data. Am J Manag Care 2005;11:449-457
21. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-574
22. Miller Jr RG. Simultaneous Statistical Inference. New York: Springer-Verlag, 1991
23. International Osteoporosis Foundation. The adherence gap: why osteoporosis patients don't continue with treatment. Available at: http://www.iofbone-health.org/publications/the-adherence-gap.html [Last accessed 16 March 2009]
24. Kertes J, Dushenat M, Vesterman JL, et al. Factors contributing to compliance with osteoporosis medication. Isr Med Assoc J 2008;10:207-213
25. Osterberg L, Blaschke T. Drug therapy: adherence to medication. N Engl J Med 2005;353:487-497